Search
Ofirnoflast
go.drugbank.com/drugs/DB21679InvestigationalOfirnoflast is a small molecule drug. The usage of the INN stem '-noflast' in the name indicates that Ofirnoflast is a inflammasome protein NLRP3 inhibitor. … Ofirnoflast is under investigation in clinical trial NCT07052006 (HT-6184 in Subjects With MDS). Ofirnoflast has a monoisotopic molecular weight of 501.15 Da.
Berotralstat
go.drugbank.com/drugs/DB15982ApprovedInvestigational[A225166] Berotralstat is strictly used to prevent, but not treat, these attacks.[L26656] Developed by BioCryst Pharmaceuticals, berotralstat is marketed under the name Orladeyo as oral capsules. … [L41960] In December 2025, the FDA expanded Berotralstat pediatric use with approval of an oral pellet formulation for prophylaxis in children with HAE aged 2 and older.[L54793,L54798]
Tradipitant
go.drugbank.com/drugs/DB12580ApprovedInvestigationalTradipitant is a selective, high-affinity antagonist at human substance P/neurokinin-1 (NK-1) receptors. … [A275353] Approved by the FDA on December 30, 2025, tradipitant is indicated for the prevention of vomiting induced by motion.
Afamitresgene autoleucel
go.drugbank.com/drugs/DB18592ApprovedInvestigational[L51114] MAGE-A4 is an intracellular cancer-testis antigen that is overexpressed by cancer cells in synovial sarcoma. … Afamitresgene autoleucel is a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T cell immunotherapy product consisting of CD4 and CD8 positive T cells transduced with a
Odesivimab
go.drugbank.com/drugs/DB15900ApprovedInvestigationalINMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320] … [A221825] Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and high
BNT162B2 Omicron (LP.8.1)
go.drugbank.com/drugs/DB23337Approved[L53723] The 2025-2026 formulation of Pfizer-BioNTech's Comirnaty was approved by the US FDA in August 2025.[L53728] … BNT162B2 Omicron (LP.8.1) is the active ingredient in the 2025-2026 formulation of Pfizer and BioNTech's Comirnaty mRNA vaccine for COVID-19.
Ruxolitinib
go.drugbank.com/drugs/DB08877ApprovedInvestigationalRuxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. … [L31958] The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo.[L39125] It is being investigated for other inflammatory skin conditions.
Diphenoxylate
go.drugbank.com/drugs/DB01081ApprovedIllicitInvestigationalWhen diphenoxylate is used alone, it is classified as a Schedule II. … This medication is classified as a Schedule V under the Controlled Substances Act by the Food and Drug Administration (FDA) and the DEA in the United States when used in preparations.
Cefotetan
go.drugbank.com/drugs/DB01330ApprovedInvestigationalThe drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms. … A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseSynonyms: (6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5- yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- carboxylic acidLatanoprostene bunod
go.drugbank.com/drugs/DB11660ApprovedLatanoprostene bunod is the first prostaglandin analog with one of its metabolites being nitric oxide (NO). … As of November 2, 2017 the FDA approved Bausch + Lomb's Vyzulta (latanoprostene bunod opthalmic solution), 0.024% for the indication of reducing intraocular pressure in patients with open-angle glaucoma